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Abstract 
Despite great strides that have been made over the past several decades in terms 
of diagnosis and treatment, breast cancer remains the most commonly diagnosed cancer 
in American women and the second leading cause of cancer-related mortality for women 
in the United States.  Although the benefits of early detection of breast cancer have been 
clearly established, the advantages of screening must also be weighed against a potential 
corresponding negative psychological impact of screening procedures.  The purpose of 
the present study was to further investigate the impact of breast cancer screening on 
previously unstudied or understudied aspects of psychological and physiological health, 
including sleep quality, negative and positive affect, and biomarkers of immune system 
response and to explore between-group differences in these markers based on diagnostic 
status over the course of time between surgical consult and diagnosis following breast 
biopsy. Results indicated substantially impaired sleep quality as well as elevations in 
negative affect across the study sample.  Higher levels of a biological marker of 
inflammation were shown to be associated with poorer sleep quality.  Positive and 
negative affect were also associated in the study sample, which is thought to be indicative 
of a high level of emotional activation during breast cancer screening and diagnosis.  
Counter to study hypotheses, results indicated neither improvements in sleep quality or 
affect nor decreased levels of serum cytokines were noted in women who received a 
benign diagnosis.  Conversely, results for several scales indicated improved sleep quality 
for women diagnosed with breast cancer relative to women who received a benign 
diagnosis, providing support for the argument that it is the experience of uncertainty that 
leads to the acute psychological distress consistently shown in women undergoing breast 
cancer screening and breast biopsy.
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During the past several decades, breast cancer has emerged as one of the most 
widely researched and most publicly supported areas within the broader field of 
oncology.  However, despite great strides that have been made in terms of diagnosis and 
treatment, breast cancer remains the most commonly diagnosed cancer in American 
women and the second leading cause of cancer-related mortality for women in the United 
States (Ferrante, Chen, & Kim, 2008).  It is estimated that approximately 1 in every 8 
American women will be treated for breast cancer at some point during her lifetime and 
that roughly 1 in every 30 of these women will die as a result of this disease (American 
Cancer Society, 2002).  As is true for many cancers, the incidence of breast cancer 
increased as women grow older, and despite progress in terms of research into 
environmental and behavioral risk factors, most cases of breast cancer will occur in 
women that do not present with identified predictors of the disease (Colditz, Willett, 
Hunter, Stampfer, Manson, & Hennekens, 1993; Seidman, Stellman, & Mushinski, 1982; 
Strax, 1987).  As risk factors alone are not sufficient to identify individuals that are likely 
to develop breast cancer, early identification and screening efforts have increased over 
the past decade.  According to the American Cancer Society (2009), in excess of one 
million women received a breast diagnostic evaluation (most commonly mammography) 
in the United States in 2008, with approximately 180,000 resulting in breast cancer 
diagnosis (Montgomery, 2010). 
The purpose of breast cancer screening is to allow for detection of the disease or 
of disease risk factors to allow for early therapeutic interventions and/or preventative 
measures, as research has shown treatments are more effective when the disease is 
diagnosed at an early stage (Wardle & Pope, 1992).  Since comprehensive breast cancer 
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screening was first implemented, research has shown that biannual mammography is the 
most effective method for reducing mortality in women 50 years or older (Kerlikowske et 
al., 1995).  Studies have shown substantial reduction in mortality rates among the general 
population of women in this age group following the introduction of biannual 
mammography into common practice (Absetz, Aro, & Sutton, 2003; deKoning, 2000).  
Two large scale controlled mammography trials conducted in Scandinavia (Tabar, 
Fagerbery, Duffy, & Day, 1989) and in North America (Shapiro, 1977) demonstrated 
greater than 30% reductions in breast cancer mortality as a result of screening.   
The utility of breast cancer screening is only achieved if mammography 
examinations are administered frequently to large numbers of women throughout the 
general population.  Such widespread implementation of mammography screening results 
not only in a great number of negative tests but also a considerable occurrence of false-
positive or inconclusive test results that require additional follow-up examination 
(Andrykowski et al., 2002).  Some studies have suggested that roughly 12 women receive 
false-positive diagnosis for every one correctly identified case of breast cancer (Wardle & 
Pope, 1992).  Medical follow-up for an abnormal mammography commonly involves 
either repeat mammography exam or the more invasive breast biopsy.  Research suggests 
that more than 80% of breast biopsies conducted following abnormal mammography 
result in benign diagnosis and exponentially higher numbers of benign diagnoses after 
repeat mammogram (Skrabanek, 1985).  According to Elmore and colleagues (1998) if 
ten screening mammograms were conducted in a woman over 50, there would be up to a 
75% chance that one false-positive outcome would result.  As breast cancer is less 
prevalent in younger women, the percentage of false-positive diagnoses would likely 
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increase for women under 40 years of age.  As predicted by Lerman and Rimer (1995), if 
40% of American women over the age of 40 were to undergo mammography screening, 
greater than three million would receive false positive or indeterminate results.   
Although the benefits of early detection of breast cancer have been clearly 
established, the advantages of screening must also be weighed against a potential 
corresponding negative psychological impact that might result from participation in 
screening procedures even when a malignancy is not identified (Lerman, Rimer, & 
Engstrom, 1991; Wardle & Pope, 1992).  Although diagnostic and curative breast cancer 
surgeries are conducted out of medical necessity, these procedures have been shown by to 
result consistently in significantly heightened distress (e.g. Deane & Degner, 1998; Ganz, 
Schag, Lee, Polinsky, & Tan, 1992; Montgomery, Weltz, Seltz, & Boybjerg, 2002).  
News of an abnormal mammogram is a stressful event that has the potential to increase 
individual vulnerability to psychological and physical illness by activating or intensifying 
pre-existing psychological issues (Alderete, Juarbe, Kaplan, Pasick, & Perez-Stable, 
2006; Brilman & Ormel, 2001).  Potential costs of screening vary from trauma resulting 
from the identification of disease in symptom-free individuals to increased psychological 
stress and anxiety in healthy individuals that receive a false-positive diagnosis (Wardle & 
Pope, 1992).  There is also a real monetary cost for screening.  For every $100 spent on 
breast cancer screening, an estimated $33 will be spent on tests that will lead to a false-
positive result (Humphrey, Helfand, Chan, & Woolf, 2002).  
Mammography screening has been shown to result in both short-term distress and 
anxiety for women with false positive diagnoses (Aro et al., 2000; Brett et al., 1998) and 
long term effects such as perceived increased risk for future diagnosis of breast cancer 
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(Aro et al., 2000).  The acute psychological distress reported might be due to the prospect 
of a grave diagnosis, fear of potential cancer treatment, the procedure of the screening 
itself which often involves uncomfortable and invasive testing procedures, as well as a 
waiting period before definitive diagnosis is made, and/or anxiety around the experience 
of a painful and untimely death (Koller, Kussman, & Lorenz, 1996; Wardle & Pope, 
1992).  Many studies have been conducted concerning breast cancer screening behavior 
as well as the psychological impact of a positive cancer diagnosis, but only a handful of 
studies have focused on the effects of cancer screening itself resulting in the notification 
of a benign diagnosis.  One study by Deane and Denger (1998) found that women who 
had received a benign diagnosis after breast biopsy demonstrated continued heightened 
anxiety and perceived uncertainty relative to those who received a positive breast cancer 
diagnosis even after they were informed of their test results.  The experience of breast 
biopsy appears to be particularly impactful.  Lindfors and colleagues (1998) found that 
women who had undergone breast biopsy with benign results reported substantially 
greater levels of distress and anxiety than those who had received a benign diagnosis after 
repeat mammogram.  Another study involving a small group of women that had recently 
undergone benign breast biopsy after abnormal mammogram found that 5 of the 30 
women described the experience as the worst event that had occurred in their lives up to 
that time (Gram, Lund, & Slenker, 1990), and two women involved in a retrospective 
study by Weil and Hawker (1997) reportedly committed suicide after receiving notice of 
abnormal mammogram results.   
Overall, a sound body of research shows that a significant number of women that 
receive a false-positive mammography test result will experience some adverse 
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psychological impact (Lipkus, Halabi, Stirigo, & Rimer, 2000).  Most commonly noted 
are increased levels of anxiety, intrusive thoughts around breast cancer, and symptoms of 
depression (Pisano, Carp & Gallant, 1998).  Elevated levels of anxiety, depression, and 
other negative emotions have been found to endure for up to five years after receipt of an 
abnormal breast cancer screening result (Lipkus et al., 2000; Pisano et al., 1998).  
Evidence has also been found that anticipatory distress occurring in the days or weeks 
prior to breast biopsy or lumpectomy is associated with post-surgical side-effects, 
including increased chance of infection and psychological symptoms including 
depression and anxiety (Montgomery & Bovbjerg, 2004).   
One explanation that has recently been put forth for the negative psychological 
impact of breast cancer screening, even when no malignancy is identified, involves the 
level of uncertainty that characterizes the screening process (Montgomery, 2010).  
Uncertainty in terms of illness has been defined as the inability of an individual to discern 
the meaning of an illness-related occurrence and an inability to ascertain an accurate 
prediction of likely outcomes (Montgomery, 2010).  This set of circumstances results in 
an infringement on a woman’s belief in herself as healthy and leads her to face the 
possibility of her own mortality (Jordens, Little, Paul, & Sayers, 2001).  Before receiving 
a benign or positive diagnosis for breast cancer, women experience a sometimes extended 
period of uncertainty as the await breast biopsy results.  Despite advances in rapidity of 
diagnosis, Ferrante and colleagues (2008) have noted an average length of time interval 
from discovery of an abnormal breast mass to definitive diagnosis ranges from 4-6 
weeks.  Further supporting uncertainty as an important factor in the distress involved in 
breast cancer screening, several studies have reported lower levels of distress when 
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communication of results is more rapid, waiting times between tests shorter, and referral 
to surgery occurs expeditiously (Barton et al., 2004; Ferrante et al., 2008).  The degree of 
uncertainty that occurs during the diagnostic process is heightened by the fact that the 
initial test, mammography, will confirm that breast cancer is possible but does not 
immediately determine whether or not a malignancy is present (Andrykowski et al., 
2002).   
The majority of published studies that have explored distress during breast cancer 
screening have noted the presence of anxiety and distress as persisting through the 
diagnostic phase, only resolving when definitive diagnosis is received.  Interestingly, 
levels of distress decrease following diagnosis, even when the diagnosis received 
indicates malignancy (Deane & Degner, 1998; Fridfinnsdottir, 1997; Shaw, Wilson, & 
O’Brien, 1994).  Levels of anxiety in women during the period of uncertainty before 
diagnosis are equivalent to those noted among patients admitted to in-patient psychiatric 
units for treatment of acute anxiety disorders (DeKeyser, Wainstock, Rose, Converse, & 
Dooley, 1998; Scott, 1983).  Concern around the psychological effects of uncertainty 
during breast cancer screening has increased since the introduction of broad screening 
programs.  The experience of breast cancer screening has been reported as negatively 
impacting treatment outcomes in women diagnosed with the disease (Thorne, Harris, 
Hislop, & Vestrup, 1999), and also impact behavioral changes in women that receive a 
benign diagnosis, including reduced likelihood that these women will comply with future 
screening recommendations (Andrykowski et al. 2002; Barton et al., 2004; Brett, 
Austoker, & Ong, 1998; Haas, Kaplan, McMillan, & Esserman, 2001; Lampic, Thurfjell, 
Bergh, & Sjoden, 2001; Lowe, Balanda, Del Mar, & Hawes, 1999; Olsson, Armelius, 
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Nordahl, Lenner, & Westman, 1999).  One study, conducted by Schnur and colleagues 
(2008), found increased levels of psychological distress in women scheduled for breast 
biopsy relative to a group of women scheduled for lumpectomy, which is a much more 
invasive procedure that can result in substantial breast tissue loss.  The authors believe 
that the increased level of uncertainty involved in breast biopsy, where diagnosis and 
need for future treatment are unknown, relative to lumpectomy, was responsible for this 
unexpected finding (Schnur et al., 2008).  In another study also conducted by Schnur and 
colleagues (2005) levels of psychological distress in pre-biopsy patients were noted to be 
higher than those found in a sample of women following definitive diagnosis of 
metastatic breast cancer. 
The evidence for the negative impact of breast cancer screening is not uniform 
and a number of studies examining the impact of false-positive cancer screening 
(abnormal mammogram followed by normal breast biopsy) have shown negative 
psychological effects to be neither severe nor persistent (Lerman et al., 1991; Wardle, 
Pernet, Collins, & Bourne, 1994).  Other researchers have shown that some psychological 
characteristics, such as active coping and social support, are positively related to well-
being in women with false-positive breast cancer screening results, which provides some 
indication that buffering effects might be possible (Blutton, Pakenham, & Buckley, 
1999). 
The majority of the literature concerned with the effects of breast cancer 
screening is not only methodologically limited, as these studies often use self-report 
measures that are retrospective in nature, but prior research has also been limited in terms 
of the psychological and behavioral characteristics that have been assessed.  State and 
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trait anxiety, depression, and breast-cancer specific worry have been the most common 
focal points, with some studies identifying heightened levels of these constructs and some 
failing to find differences between women undergoing breast cancer screening and 
control samples (Ekeberg et al., 2001).  While prior research has examined the impact of 
breast cancer screening on specific aspects of mood/affective state, primarily depression 
and anxiety, and behavior in terms of coping strategies, none to date have been conducted 
that explore a more balanced mood profile, including both positive and negative affect, or 
that examine the impact of screening on specific daily behaviors, such as sleep, 
commonly effected by stress.  In addition, although prior research has shown a clear 
profile of immune system changes following breast cancer treatment (Lutgendorf, 2009; 
Sepah & Bower, 2009), few studies have explored the potential impact of the breast 
cancer screening process on biological markers of immune system functioning.  One 
possible explanation for the variability of findings evidenced in the literature is that the 
measures commonly included in test batteries are not picking up effects specific to the 
short-term experience of acute stress that characterizes breast cancer diagnostic 
screening.   
Although a great deal of support has been shown for the increased prevalence of 
depressed mood, anxiety, and chronic stress in patients undergoing treatment for breast 
cancer (eg. Gram et al., 1990; Koller, Kussman, & Lorenz, 1996; Pisano et al., 1998), it is 
possible that the impact of screening and diagnosis is manifesting across a broader profile 
of symptoms.  In order to investigate this possibility, the present study seeks to examine 
the impact of breast cancer screening and early diagnosis on several constructs known to 
impact in patients undergoing treatment for breast cancer that have been widely 
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understudied in women undergoing breast cancer screening.  These include sleep quality, 
mood state in terms of both positive and negative affect, and immune system functioning.   
To date, only one published study has investigated immune system (DeKeyser, 
Wainstock, Rose, Coinverse, & Dooley, 2004) functioning during breast cancer screening 
in women that will go on to receive both benign and positive diagnoses, and a recent 
review of the literature has not identified a single published study examining the impact 
of breast cancer screening on sleep or negative and positive affect.   
Sleep and Affect.  At the National Institute of Health State of the Science 
conference (NIH, 2004), sleep and mood disturbance were identified as the most 
frequently occurring and debilitating symptoms of cancer and cancer treatments.  Sleep 
quality has been shown to impact reported symptoms of fatigue, pain tolerance and 
severity, and immune system functioning; poor sleep has been related to symptoms of 
depression and anhedonia (Dickstein & Moldofsky, 1999; Sheev, 1996; Irwin, 2002).  
Although the impact of breast cancer screening on sleep quality and quantity has not been 
fully explored to date, problematic sleep has been established as a significant issue for 
cancer patients and is often the target of pharmacological intervention as a part of 
adjuvant cancer treatment (Derogatis, Feldstein, & Morrow, 1979; Goldberg & Mor, 
1985).  Although figures have varied widely, the overall prevalence of significant sleep 
disturbance in cancer patients has been estimated to be as high as 95% (Thomas, 1987).  
While the number of studies that have investigated the rates of sleep disturbance in 
women suffering from breast cancer is limited, the existing literature notes that these 
patients frequently report unsatisfactory sleep and experience sleep problems, including 
10 
 
frequent awakenings, while undergoing chemotherapy or radiation treatment (Carpenter 
& Andrykowski, 1998; Berger, 1995; Berger, 1998; Berger & Farr, 1999; Knobf, 1986)  
One study found a high percentage of sleep disturbance in a sample of women 
undergoing treatment for breast cancer and also demonstrated that these sleep problems 
predicted lower self-reported quality of life (Fortner, Stepanski, Wang, Kasprowicz, & 
Durrence, 2002).  The authors also noted that while patients that were currently 
undergoing treatment for breast cancer (radiation or chemotherapy) showed a trend 
toward greater sleep disturbance, that levels of sleep disturbance in these patients was not 
higher than in those that were not currently undergoing treatment.  This would suggest 
that sleep problems in cancer patients are not entirely due to the negative effects of 
radiation and chemotherapy treatments.  One possible explanation for this finding might 
be that the sleep issues reported by cancer patients might be due in part to psychological 
factors, such as stress, anxiety, or depression, that have been shown to impact sleep 
quality in otherwise physically healthy individuals (Fortner et al., 2002; Lutgendorf & 
Costanzo, 2003; Spiegel & Sephton, 2001; Antoni, 2003). 
Importantly, several investigators have cited changes in sleep quality as early 
symptoms of a broader pattern of systemic dysregulation.  Dysregulation of several 
interconnected circadian systems has been demonstrated in women with breast cancer, 
including the adrenal system, the stress response system, and the autonomic nervous 
system, which is responsible in part for sleep regulation (Bovbjerg, 2003; Sephton and 
Spiegel, 2003; Touitosu, Bogdan, Levi, Benavides, & Auzeby, 1996).  Dysfunction 
across these symptoms has also been shown to be associated with a more rapid course of 
disease progression in some cases (Bovbjerg, 2003; Sephton and Spiegel, 2003; Touitosu 
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et al., 1996).  Other factors, such as high levels of stress and psychological disorders such 
as depression, may contribute to disruption of normal circadian rhythms and might 
therefore indirectly contribute to shorter survival time in breast cancer patients (Antoni, 
2003; Carlson, Campbell, Garland, & Grossman, 2007; Lutgendorf & Costanzo, 2003; 
Spiegel & Sephton, 2001).  Therefore, changes in sleep pattern and/or sleep quality might 
provide a useful marker of risk for disruption of normal circadian rhythm and comorbid 
psychological symptomology.  As sleep quality is also related to psychological factors 
such as anxiety and depression, it is possible that sleep disturbance or changes in sleep 
quality might be evident in women undergoing breast cancer screening even if symptoms 
of depression and anxiety are not detectable.   
Mood disturbance has also been noted in non-cancer populations as associated 
with multiple physical, immunological, and psychological changes, including increased 
reported severity of pain, increased levels of pro-inflammatory cytokines, and increased 
symptoms of depression (Bardwell et al., 2006; Lee et al., 2004; Weitzner et al., 1997).  
Approximately 20-40% of women with breast cancer experience and report experiencing 
mood disturbances at some point during the course of treatment (Badger et al., 2004).  
Although several studies have found support for increased symptoms of subjective 
distress, most commonly measured via assessment of depression or anxiety, in women 
undergoing breast cancer screening, results have been inconsistent (e.g., Ekeberg et al., 
2001).   
In order to further explore mood disturbance in women in the diagnostic phase of 
breast cancer treatment, the present study will explore the impact of screening and 
diagnosis on levels of self-reported positive and negative affect.  Positive and negative 
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affect are commonly described as independent constructs that represent separate but 
related components of mood state (Watson, Clark, & Tellegen, 1999).  Positive and 
negative affect are representative of dimensional mood states with high negative affect 
characterized by the experience of subjective distress and unpleasurable engagement 
while positive affect represents subjective feelings of satisfaction and pleasurable 
engagement with one’s environment (Watson & Clark, 1984).  High levels of positive 
affect have been associated with high energy, extraverted behavior, improved 
concentration, and emotions such as enthusiasm and alertness, and low levels of positive 
affect are related to feelings of sadness, disengagement, and lethargy (Crawford & Henry, 
2004).   Alternatively, high negative affect is related to neuroticism, anxiety, and the 
emotional experience of guilt, anger, fear and nervousness, while low negative affect is 
related to feelings of calmness, relaxation, and serenity (Crawford & Henry, 2004).  By 
including measures of both positive and negative affect in the present study, we hope to 
not only discern the presence of negative emotional activation but also to examine the 
impact of breast cancer screening on positive emotional activation, an area that has to 
date remained unexplored.   
Immune System Markers.  As was discussed above, individuals suffering from 
chronic illnesses, including cancer, often exhibit diverse psychological symptomology 
including fatigue, anxiety, and depression (e.g., McDaniel, Musselman, Porter, Reed, & 
Nemeroff, 1995).  Although the traditional method for assessment of psychological 
symptoms has been via self-report questionnaire or interview-based measures, prior 
clinical research suggests a strong relationship between disease related inflammation and 
depression in patients suffering from chronic illnesses, including diabetes, obesity, and 
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coronary heart disease (Frasure-Smith & Lesperance, 2006).  Support for this relationship 
has led researchers over the past two decades to explore measurement of biological 
markers of immune-related inflammation as a non-self-report technique for assessing 
level of psychological and physiological distress (Glaser, Robles, & Sheridan, 2003; 
Konsman, Parnet, & Dantzer, 2002; Reichenberg, Yirmiya, & Schuld, 2001).  
Inflammatory cytokines are one such biological marker.   
 Cytokines are known to function as signaling molecules that are related to the 
regulation of cellular inflammation and are produced by cells that regulate the human 
immune response (Thomson & Lotze, 2003).  While multiple classification systems for 
cytokines have been developed, these molecules are largely divided into two distinct 
groups:  cytokines that promote inflammation, termed pro-inflammatory cytokines, and 
those that reduce inflammation, referred to as anti-inflammatory cytokines (Dinarello, 
2000).  Pro-inflammatory cytokines are particularly important in terms of their role in 
communication of immune activity to the central nervous and neuroendocrine systems 
(Reichlin, 1993).  For example, when an infection is present somewhere in the body, 
immune regulating cells release pro-inflammatory cytokines which act by signaling for 
increased pituitary and adrenocortical secretions to combat pathogens (Blalock, 1989).  
 Unfortunately, pro-inflammatory cytokines are also involved with chronic 
inflammation which has been associated with greater morbidity of diseases including 
cardiac disease, cancer, and diabetes (Black, 2003).  Chronic inflammation has also been 
noted as a contributing factor in cancer proliferation and has been associated with 
mortality in breast cancer patients (Hagemann et al., 2007; Pierce et al., 2009).  More 
positive factors such as positive affect and social support have been associated with 
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decreased levels of proinflammatory cytokines (Chida & Steptoe, 2008; Rhyff et al., 
2004).  Long term exposure to high concentrations of stress hormones instigates an 
immune system response that diminishes the immune system’s ability to respond to the 
body’s anti-inflammatory actions, resulting in higher levels of pro-inflammatory 
cytokines. (Miller, Cohen, & Richey, 2002).  Although few studies have assessed levels 
of pro-inflammatory cytokines in breast cancer patients, research has shown that positive 
affect in breast and prostate cancer patients is related to higher levels of inflammatory 
cytokines and Interleukin-6 (IL6), an endogenous cytokine, across multiple measurement 
time-points during a 6-week course of external beam radiation therapy (Seraph & Bower, 
2009).  In contrast, prior research has also indicated that cancer patients who are high in 
positive affect before treatment may have a more efficient inflammatory response, as 
reflected in higher levels of pro-inflammatory cytokines during treatment (Lutgendorf, 
2009).     
During the course of an illness, especially one characterized by prolonged 
symptoms such as breast cancer, depression and irritability are often reported as well as 
mild cognitive issues including impairment of attention, concentration, and short-term 
and working memory (Dantzer, O’Connor, Freund, Johnson, & Kelley, 2006).  The 
symptoms commonly associated with sickness are in fact largely due to the body’s 
immune response, which is characterized by changes in the autonomic and endocrine 
systems triggered by accessory immune cells and mediated by pro-inflammatory 
cytokines (including C-reactive protein and IL-6).  C-reactive protein (CRP) is an acute 
phase protein that is associated with systematic inflammation in the body (American 
Heart Association, 2010).  As was previously stated, pro-inflammatory cytokines 
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function by coordinating the body’s local and systemic inflammatory response to 
pathogens in order to combat infectious agents.  However, pro-inflammatory cytokines 
can also act on the brain and the periphery to cause sickness symptoms including fatigue 
and depression (Dantzer et al., 2006).   
In the past decade, researchers have found that the immune response can cause 
not only symptoms associated with sickness but can also can result in psychological 
symptoms, including anxiety and depression, in physically ill individuals with no history 
of mental disorder (Dantzer et al., 2006).  For individuals with cancer, a prolonged 
immune response to the presence of tumor cells leads to an overabundance of pro-
inflammatory cytokines (Coussens & Werb, 2002).  High levels of interleukin-6 (IL-6), a 
common circulating pro-inflammatory cytokine, have been associated with more negative 
outcomes in patients with breast cancer (Zhang & Anachi, 1999), and IL-6 is thought to 
stimulate increased tumor cell growth and to contribute to recurrence and metastasis of 
breast cancer (Balkwill & Mantovani, 2001; Leek & Harris, 2002).  IL-6 has also been 
associated with disease stage progression in breast cancer (Rao, Dyer, Jameel, Drew, & 
Greenman, 2006).  Pro-inflammatory cytokines have also been associated with symptoms 
of depression (Musselman et al., 2001) and fatigue (Bower et al., 2000) in breast cancer 
patients.  Although elevated levels of proinflammatory cytokines have been related to 
increased rate of disease progression in cancer patients, the findings have been somewhat 
inconsistent (Lyon, McCain, Walter, & Schubert, 2008).  Some studies have found 
differences in level of pro-inflammatory cytokines in breast cancer v. controls (Lyon et 
al., 2008) and some have not (Pusztai et al., 2004). 
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Although multiple studies have explored the involvement of pro-inflammatory 
cytokines in breast cancer, to our knowledge only one published study has investigated 
markers of immune function in women undergoing breast cancer screening.  DeKeyser 
and colleagues (2004) looked at distress and immune function in women with suspected 
breast cancer.  The authors reported associations between psychological distress, 
symptom distress, and levels of a serum cytokine, tumor necrosis factor alpha.  However, 
the authors did not find differences in levels of cytokines between women with a benign 
diagnosis and women diagnosed with breast cancer (DeKeyser et al., 2004).  In order to 
further explore immune system functioning in women undergoing breast biopsy and also 
to explore potential associations between immune markers, mood state, and sleep quality, 
the present study will involve measurement of two known immune response markers: IL-
6 and CRP before and after breast biopsy.   
Summary.  Overall, prior research consistently suggests that the screening and 
early diagnostic phase of breast cancer treatment represents an acutely stressful 
experience for women.  Several studies have noted increased symptoms of distress, 
depression and anxiety occurring during this time, with some studies reporting continued 
elevations in negative psychological symptoms persisting for months to years following 
even a benign diagnosis.  One possible explanation for the distress that characterizes the 
diagnostic phase for breast cancer is the prolonged period of uncertainty experienced by 
women awaiting diagnosis via breast biopsy following abnormal mammogram.  Although 
a substantial amount of research has explored depression, anxiety, social support and 
coping skills in women with suspected breast cancer, none to date have explored the 
impact of breast cancer screening on positive and negative affect or sleep quality.  In 
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addition, only one published study to date has investigated levels of pro-inflammatory 
cytokines in women undergoing breast biopsy, and no study to date has explained the 
associations of these factors.  
 The purpose of the present study is to further investigate the impact of breast 
cancer screening by exploring changes in sleep, negative and positive affect, and 
biomarkers of immune system response, during the time between abnormal 
mammography and diagnosis following breast biopsy in a population of women with 
suspected breast cancer.  As no prior research has involved an examination of sleep 
quality or negative and positive affect, the first primary aim of the present study is to 
determine if levels of sleep difficulty and affect are elevated in women with suspected 
breast cancer relative to normative samples.  Then, we will explore potential relationships 
among study measures to determine if associations between serum cytokine levels, sleep 
quality, and affect are present in women undergoing breast cancer diagnostic testing.  We 
will also explore any changes that might occur in terms of study variables before and 
after breast cancer diagnosis.  Finally, the study sample will be split into two subgroups 
based upon diagnosis and potential between-group differences in sleep quality, affect, 
and immune markers will be examined.   
 Based upon prior research that has consistently reported increased psychological 
distress among women with suspected breast cancer, we expect that our study sample will 
demonstrate decreased sleep quality, decreased positive affect, and increased negative 
affect relative to normative PSQI and PANAS scale scores.  We also expect that these 
elevations will decrease post-biopsy for the benign diagnosis group but will remain stable 
for those diagnosed with breast cancer.  Elevations in serum cytokine levels are also 
18 
 
expected to increase during the pre- to post-biopsy period for both groups due to the 
stressful nature of the experience of breast cancer diagnostic testing.  Finally, we expect 
to find associations between sleep quality, affect, and immune markers for both the 
benign diagnosis and positive breast cancer diagnosis groups. 
Method 
Participants and Procedure.  Participants for this study were a convenience 
sample taken from a group of 100 consecutive patients who have been referred to the 
surgeons of the Neag Comprehensive Cancer Center for evaluation.  The study sample 
consisted of women from 20-80 years of age who have been referred for follow up 
evaluation after an abnormal breast exam or mammogram.  Participants were approached 
by study staff during their initial surgical consult and asked to complete two short series 
of questionnaires and to provide blood samples for biological analyses.  Pre-biopsy 
questionnaires were completed following initial surgical consult for breast biopsy.  Post-
biopsy questionnaires were completed after participants obtained results of their breast 
biopsy.  Participants had the option to complete questionnaires either in the consult office 
within the cancer center or via a web-based survey from home if preferred.  Biopsy 
results were retrospectively determined at the time of data consolidation from 
participants’ pathology reports and charts.   
Measures 
Pittsburgh Sleep Quality Index (PSQI).  The Pittsburgh Sleep Quality Index 
(PSQI; Buysse, Reynolds, Monk, Berman, & Kupfer, 1989) is a standardized self-report 
measure of sleep quality designed to determine patterns of sleep dysfunction through 
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assessment of both qualitative and quantitative data and also to allow for calculation of a 
single global score to convey quality and severity of overall sleep problems (Carpenter & 
Andrykowski, 1998).  A global PSQI score above 5 is considered as an indication of 
significant sleep disturbance (Buysse, Reynolds, Monk, Berman, & Kupfer, 2000).  The 
PSQI consists of 19 items that, taken together, produce a single global sleep quality index 
as well as seven component scores aimed at representing standard areas most commonly 
assessed by clinicians.  These component scores reflect sleep quality, sleep latency, sleep 
duration, sleep efficiency, sleep disturbance, use of sleep medications, and daytime 
dysfunction.  The PSQI also collects information about typical bed time, wake time, 
number of actual hours slept, and number of minutes to fall asleep.  The other fifteen 
PSQI items are forced-choice Likert-type scales.  Higher scores on the global index as 
well as the seven component scales represent poorer sleep quality.  The psychometric 
properties of the PSQI were originally supported with data collected from a sample of 52 
healthy subjects and 96 individuals with a history of sleep problems (Buysse et al., 1989).  
Since that time, the PSQI has been utilized in a variety of populations, including healthy 
individuals of varying ages (Hoch, Dew, Reynolds, & Monk, 1994), trauma survivors 
(Mellman, Kulick-Bell, Hebding, & Nolan, 1995), and patients with mood disorders, 
panic disorders, social phobia, and breast cancer patients (Nierenberg, Adler, Peselow, 
Zornberg, & Rosenthal, 1994; Pasternak, Reynolds, & Houck, 1994; Reynolds, Hoch, & 
Buysse, 1993; Stein, Chartier, & Walker, 1993).  The PSQI has demonstrated internal 
consistency, convergent and discriminant construct validity, and consistent Chronbach’s 
alphas across multiple samples (Carpenter & Andrykowski, 1998).   
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Positive and Negative Affect Schedules (PANAS).  The Positive and Negative 
Affect Schedule (PANAS; Watson et al.,1988) is a 20-item self-report measure that 
consists of two 10-item mood scales which represent positive and negative affect 
respectively.  The PANAS was developed using a sample of undergraduate students but 
has since been validated with a wide variety of adult populations.  Each of the 20 items is 
rated on a 5-point forced-choice Likert-type scale ranging from 1 (very slightly or not at 
all) to 5 (extremely) the indicate the degree to which the participant endorses a particular 
feeling state within a specified time frame.  Scores for each affect scale range from 10-
50, with higher scores representing higher levels of negative or positive affect.  Results of 
a recent study with a large, non-clinical sample of 1,003 members of the general adult 
population provided normative data for both positive (mean = 31.31, SD = 7.65) and 
negative (mean = 16, SD = 5.9) affect scales (Crawford & Henry, 2004).  Time frame for 
the PANAS can be adjusted to reflect positive and negative affect for any range from in 
the present moment to over the course of the last year.  Watson, Clark, and Lee (1998) 
have demonstrated alpha coefficients for various time reference periods ranging from .84 
to .90.  Both subscales of the PANAS have also been shown to demonstrate discriminant 
and convergent validity with other established measures.  The two scales have been 
shown to be highly internally consistent and stable (Watson, 1988).   
Interleukin-6 (IL-6) and C-Reactive Protein (CRP).  Blood samples were 
collected from participants via inner elbow venipuncture and collected into vacutainer 
tubes.  Samples were prepared via centerfuge and serum was collected and subsequently 
frozen at negative eighty degrees celcius.  Serum was then analyzed for levels of IL-6 and 
CRP using Luminex Multiplex Bead assays according to manufacturer’s instructions. 
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Data Analyses.  To ensure a normal distribution of scores, values above or below 
three standard deviations of the mean for CRP and IL-6 were removed for further 
analyses.  Square root and natural log transformations were then conducted for CRP and 
IL-6, respectively.  Non-detectable levels of IL-6 were designated as zero values for 
subsequent analyses. 
All data analyses were performed using SPSS version 17.0 (SPSS, Inc., 2009).  
We first conducted exploratory data analyses to assess demographic composition of the 
sample.  Bivariate correlation matrices were then computed in order to determine 
associations between self-report measures (PSQI and PANAS) and biological markers 
(CRP and IL-6), and between these variables and potential covariates.  Potential 
covariates included age of participants, time interval between pre- and post-biopsy time 
points, as well as several self-report questionnaire measures.  Self-report measures 
included the Hospital Anxiety and Depression Scale (HADS; Zigmond & Snaith, 1982), 
which detects states of depression and anxiety in medical patients; the European 
Organization for Research and Treatment of Cancer quality of life questionnaire 
(EORTC; Aaronson et al., 1993), which assesses quality of life in cancer patients; and the 
Brief Fatigue Inventory (BFI; Mendoza et al., 1999), which assesses fatigue in clinical 
settings.  The data were then spit into subgroups based on cancer diagnosis and 
correlational analyses were repeated.  Partial correlation matrices were then computed in 
order to allow for determination of associations between all study measures with 
covariates included.  General linear model repeated measures tests were conducted to 
examine change in study measures over time with cancer diagnosis as a between subjects 
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variable.  Finally, residualized change scores were computed to further examine 
relationships between study measures over time.   
Results 
Participant Characteristics.  Relevant demographic information for the total 
study sample as a whole and sub-grouped by diagnostic status is detailed in Table I.  
Although complete questionnaire and biological data were obtained for a total of 47 
participants, limited demographic data were available.  The average age of participants 
was 53-years-old (SD = 10.67).  The interval of time between completion of the two sets 
of study questionnaires varied with a mean time to completion of 25.5 days (SD = 26).   
The study sample was comprised predominantly of Caucasian women (51.1%) with small 
numbers of African-American (4.3%) and Hispanic (6.4%) also included.   Information 
regarding ethnicity was not available for 18 of 47 participants.  All participants 
underwent surgical breast biopsy over the course of their participation in the present 
study, with 32 (68.1%) women receiving a benign diagnosis and 15 (31.9%) diagnosed 
with breast cancer.   
Descriptive Statistics for Study Measures.  Descriptive characteristics for all study 
scales and biological markers are detailed in Tables IIa and IIb.  The average detected 
serum concentration of CRP at the pre-biopsy time point was 7,248.06 mg/dL (SD = 
7,823.91) and at post-biopsy was 8,358.26 mg/dL (SD = 8,597.71).  Mean detected IL-6 
at the pre-biopsy time point was 252.168 pg/mL (SD = 545.15) and at post-biopsy was 
245.86 pg/mL (SD = 518.55).  At the pre-biopsy time point, average score on the PANAS 
positive affect (PA) subscale was 25.1 (SD = 6.1), which is within normal range for this 
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scale.  Post-biopsy average negative affect (NA) score was 29.79 (SD = 6.34).  This score 
is more than two standard deviations above the mean score for normative samples.  At the 
post-biopsy time point, average PA was 23.75 (SD = 6.51), which is within normal range.  
Post-biopsy average NA score was 29.32 (SD = 7.44), which is also more than two 
standard deviations above the normative mean score.  Average global PSQI index score 
at pre-biopsy was 7.27 (SD = 3.31) and post-biopsy average score was 7.02 (SD = 3.59).  
The majority of participants demonstrated significant sleep disturbance (average score 
above 5) at both the pre- and post- biopsy time points, regardless of cancer status.    
Associations between PSQI, PANAS and Biological Markers.  Correlation 
coefficients were calculated to explore potential associations between study measures and 
potential covariates.  Partial correlation coefficients were then calculated to explore these 
associations while statistically controlling for anxiety (HADSA), depression (HADSD), 
well-being (EORTC), and fatigue (BFI) at baseline.  Results are detailed in Table III.   
 Transformed CRP at both pre- and post-biopsy time points was positively 
associated with post-biopsy PSQI scores (r = .384, p<.05; r = .375, p<.05).  Transformed 
IL-6 was not associated with any other study measure.  Both positive and negative affect 
at the pre-biopsy time point were associated with positive (r = .798, p<.01) and negative 
(r = .917, p<.01) affect post-biopsy.  The PANAS positive affect subscale was also 
shown to be positively associated with the negative affect subscale at both pre-biopsy (r = 
.492, p<.05) and post-biopsy (r = .459, p<.05) time points. 
 Data were then split into two subgroups based upon diagnostic status and partial 
correlation coefficients were once again computed.  For participants with a benign breast 
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cancer diagnosis, post-biopsy transformed CRP was associated with post-biopsy PSQI (r 
= .482, p = .05) but not with pre-biopsy PSQI, although that relationship did approach 
significance (r = .429, p = .086).  For participants with a positive diagnosis of breast 
cancer, pre-biopsy transformed CRP was associated with pre-biopsy negative affect (r = 
.758, p<.05).  No associations between IL-6 and other measures were found for either 
group.  No associations were found between PSQI and other measures.  Pre-biopsy 
positive affect for participants with a benign diagnosis was shown to be related to post-
biopsy positive affect (r = .795, p<.01) and to post-biopsy negative affect (r = .851, 
p<.01) and time two (r = .753, p<.01).  Pre-biopsy negative affect for these participants 
was associated with post-biopsy negative affect (r = .680, p<.01) and to post-biopsy 
positive affect (r = .769, p<.01).  For participants with a positive cancer diagnosis, pre-
biopsy positive affect was associated with pre-biopsy negative affect (r = .824, p<.05) but 
not with positive or negative affect post-biopsy.  Pre-biopsy negative affect for this group 
was associated with post-biopsy negative affect (r = .459, p<.05) and post-biopsy positive 
affect was associated with post-biopsy negative affect (r = .898, p<.05).   
PSQI Component Scales.  General linear model repeated measures analyses were 
conducted to explore potential main effects (cancer status and time point) as well as 
interaction effects (cancer status x time point) for PSQI component scales.  For all PSQI 
component scales, a higher score indicates increased impairment.  For all analyses, time 
interval between pre- and post-biopsy time points was entered as a covariate.  Results are 
depicted in Figures 1-3.  For the PSQI component score reflecting sleep latency, a 
significant interaction effect was found between time point and cancer status (F(1, 33) = 
4.725, p<.05), indicating a pre- to post-biopsy improvement in sleep latency scores for 
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participants diagnosed with breast cancer relative to those with a benign diagnosis.  No 
significant main effects were demonstrated for diagnostic status or for time point.  A 
similar result was shown for the PSQI component score representing daytime 
dysfunction, with a significant interaction effect between time point and cancer status 
(F(1, 33) = 7.008, p<.05), indicating a pre- to post-biopsy improvement in daytime 
dysfunction scores for participants diagnosed with breast cancer relative to those with a 
benign diagnosis.  No significant main effects were found for cancer diagnostic status or 
for time point.   
Group Differences in Immune Response Markers and Affect.  General linear 
model repeated measures analyses were also conducted to explore potential main effects 
(cancer status and time point) as well as interaction effects (cancer status x time point) for 
PSQI global scores, PANAS positive and negative affect scales, CRP and IL-6.  No 
significant main effects or interaction effects were found for PSQI, PANAS positive and 
negative affect scales, or IL-6.  However, a significant main effect was found for CRP 
(F(1, 41) = 4.241, p<.05), indicating an increase in transformed CRP from pre- to post-
biopsy regardless of cancer diagnosis (see Figure 4).  No significant main effect for 
cancer status or significant interaction between cancer status and time point was found.  
Results are detailed in Figure 4. 
 In order to further examine relationships between study scales and immune 
markers, residualized change scores were computed for PANAS positive and negative 
affect scales, PSQI global scores, transformed CRP and transformed IL-6.  Delta scores 
for each of these variables were created and entered into stepwise linear regression 
analyses.  Post-biopsy values served as dependant variables.  Covariates were entered as 
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level-one independent variables, pre-biopsy values were entered as level-two independent 
variables, and delta scores were entered as level-three independent variables.  Following 
initial analyses, data were split into subgroups by diagnostic status and residualized 
change scores were calculated once again.   
 Initial analyses conduced with the total sample did not indicate that any of the 
independent variables accounted for a significant change in level of CRP over time.  
However, when the data were split by cancer diagnosis, results indicated that for women 
who received a benign diagnosis, scores on the PANAS positive affect scale increased 
with levels of CRP (F(1,18) = 7.728, p <.05, β = .279).  A trend toward significant was 
also noted for change in PANAS negative affect scores occurring with increased level of 
serum CRP in the benign group (F(1,18) = 3.022, p = .99, β = .194).  A similar finding 
was also noted when PANAS positive affect score was entered as the dependent variable 
for the total study sample, with increased positive affect increasing as serum CRP 
increased (F(1,41) = 8.168, p <.01, β = .276).  A significant relationship was also 
indicated between increases in positive and negative affect over time for the total sample 
(F(1,43) = 9.125, p <.01, β = .299).  When data were broken into subgroups by diagnostic 
status, no significant relationships were noted between positive affect and other variables 
for women diagnosed with breast cancer.  For the benign group, however, the relationship 
between positive and negative affect persisted (F(1,20) = 6.489, p <.05, β = .260).  When 
PANAS negative affect score was entered as the dependent variable for the total sample, 
a significant relationship between positive and negative affect was indicated once again 
(F(1,40) = 6.245, p <.05, β = .247).  No significant residualized change scores were noted 
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for negative affect when data were split by diagnosis.  No significant residualized change 
scores were noted when IL-6 or PSQI index score were entered as a dependent variables.  
Discussion 
 The overarching purpose of the present study was to further investigate the impact 
of breast cancer screening on previously unstudied or understudied aspects of 
psychological and physiological health, including sleep quality, negative and positive 
affect, and biomarkers of immune system response.  This study further aimed to explore 
between-group differences in serum cytokine levels, sleep quality, and affect based on 
diagnostic status over the course of time between surgical consult and diagnosis 
following breast biopsy in order to determine whether receipt of a benign diagnosis will 
significantly reduce level of psychological distress.  To this end, measurement of sleep 
quality, positive and negative affect, and serum cytokines was conducted at two time 
points, pre- and post- surgical breast biopsy, in a convenience sample of women referred 
to the Neag Comprehensive Cancer center for evaluation of an abnormal breast mass.   
 A total of 47 participants completed questionnaire and biological measures at both 
study time points.  Although limited demographic information was available for this 
sample, participants were primarily women of a typical age for breast cancer screening 
with an average age of 53-years-old, and were primarily Caucasian.  All women 
underwent a surgical breast biopsy procedure over the course of the study.  Of the 47 
participants that completed the study, 32 received a benign diagnosis and 15 were 
diagnosed with breast cancer.  These figures are also consistent with percentages reported 
in large scale studies (deKoning, 2000; Wardle & Pope, 1992).   
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 As the measures included in the present study had not previously been assessed in 
a similar patient population, we first calculated basic descriptive statistics for the group as 
a whole, and then by diagnostic subgroup, in order to compare average scores on the 
PSQI and PANAS scales for our sample with normative data available for these 
measures.  As past research consistently reports elevated levels of psychological distress, 
we expected that scores on both scales would be significantly elevated relative to 
normative data (Crawford & Henry, 2004; Watson et al., 1998).  Results confirmed our 
hypotheses.   For the sample as a whole as well as for diagnostic sub-groups, mean PSQI 
global index scores were above the level established by creators of the measure as 
indicative of significant sleep disturbance (global score >5).  This was true at both pre- 
and post-biopsy time points.  We next examined the PANAS subscales reflecting 
negative and positive affect.  As no cut-off scores have been established for this measure, 
we used as a comparison sample data from a large (1,003) general population sample of 
adult men and women (Crawford & Henry, 2004).  Results indicated that while positive 
affect for the total sample and sample subgroups was within normal range at both pre-and 
post-biopsy time points.  Results for the negative affect scale, however, revealed 
substantial elevations in negative affect (greater than two standard deviations above the 
normative sample mean) for the total sample and subgroups at both time points.  These 
results not only provide additional evidence of the stressful nature of breast cancer 
diagnostic testing but also provide an initial indication that sleep and mood state are 
negatively impacted during the breast cancer diagnostic phase. 
 Another aim of this study was to examine associations between sleep quality, 
negative and positive affect, and serum cytokine levels.  To serve this purpose, partial 
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correlation analyses were conducted to evaluate relationships between these study 
variables.  In order to control for potentially confounding factors, anxiety, depression, 
well-being, and fatigue were statistically controlled for these analyses.  As sleep quality, 
negative and positive affect, and levels of serum cytokines have been shown to be 
impacted during stressful experiences (e.g. Gram et al., 1990; Pisano, Earp, Schell, 
Vokaty, & Denham, 1998; Wardle & Pope, 1992), we expected that relationships would 
emerge between these study variables for our sample.  Our hypotheses were partially 
confirmed by analyses conducted with the total sample.  Results indicated that higher 
levels of serum CRP at both time points were associated with poorer sleep quality at the 
post-biopsy time points.  This finding indicates that women who were experiencing and 
reporting lower quality of sleep post-biopsy also demonstrated increased levels of this 
circulating pro-inflammatory cytokine, a biological marker of stress-related immune 
system activation.  However, no such associations were found between IL-6 and the other 
study scales.  Although this finding does not support our hypotheses, it is likely that our 
failure to detect relationships between IL-6 and the other study scales is due at least in 
part to the high number of participants with non-detectable levels of IL-6.  In order to 
include these participants’ data for analyses, non-detectable levels were entered as zero, 
which resulted in a negatively skewed distribution, potentially inhibiting our ability to 
statistically detect associations.  As other studies have shown that decreases in IL-6 are 
associated with the distress experienced by patients undergoing cancer screening (Glaser 
et al., 2003; Konsman et al., 2002; Reichenberg et al., 2001), it is likely that we would 
have seen similar results if the variability of our data were not limited. 
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 An additional unexpected finding also emerged from correlational analyses.  
Results indicated a positive association between positive and negative affect for the total 
sample at both pre- and post-biopsy time points, suggesting that participants with higher 
levels of positive affect also demonstrated higher levels of negative affect.  This is 
somewhat unusual as prior literature consistently reports negative correlations between 
these two scales (Watson, 1998).  Although positive and negative affect are now widely 
considered to reflect distinct constructs, elevated levels of both positive and negative 
affect are not typically noted in prior research.  However, as was previously discussed, 
the diagnostic phase of breast cancer treatment represents a highly stressful experience 
that is characterized by anxiety and psychological distress.  As high levels of both 
positive and negative affect represent emotional activation (Watson et al., 1988), it is 
fitting that elevations across these scales would be exhibited by women undergoing a 
highly emotionally activating experience.  As lower levels of positive affect are typically 
associated with symptoms of depression (Crawford & Henry, 2004), these results are 
consistent with prior research that has not found a substantial increase in depression for 
women undergoing breast biopsy relative to healthy samples (Ekeberg et al., 2001).   
 Following these group-wide analyses, the sample was divided into subgroups 
based on cancer diagnosis and analysis of associations between study measures was 
repeated.   Results for the benign group once again indicated an association between 
serum CRP and sleep quality, with higher CRP related to poorer post-biopsy sleep quality 
for this group.  This relationship was not detected in the breast cancer group.  However, it 
is unclear whether this is truly reflective of a lack of association or to a lack of statistical 
power due to the limited number of participants in this subgroup.  Despite the small 
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number of participants in the positive diagnosis group, negative affect for this group was 
related to level of serum CRP, indicating that participants with higher pre-biopsy 
negative affect also demonstrated higher levels of pre-biopsy serum CRP.  This finding is 
in keeping with study hypotheses that predicted associations between study measures 
indicating psychological distress and serum cytokine levels.  The group-wide relationship 
between positive and negative affect was also demonstrated by sub-group analyses.  For 
both the benign and positive diagnosis subgroups, participants with higher levels of 
negative affect also demonstrated higher levels of positive affect at both pre-and post-
biopsy time points.  If the association between high positive and negative affect is 
reflective of a broad emotional activation resulting from an acutely stressful experience, 
than these results might be taken as support for the assumption that breast cancer 
screening is associated with acute emotional activation even for women who receive a 
benign diagnosis.   
 To further examine the relationship between changes in PSQI, PANAS scales, 
and cytokine levels over time, residualized change score analyses were conducted.  
Results of these analyses further supported the presence of high levels of both positive 
and negative affect across diagnostic subgroups.  Not only was increased positive affect 
predictive of increases in serum CRP for women who received a benign diagnosis, but 
increases in positive affect were predictive of increases in negative affect both for the 
group as a whole and within each diagnostic subgroup. 
 Another aim of the present study was to determine whether participants would 
demonstrate a differential pattern of impairment in terms of sleep quality, affect, and 
serum cytokine levels depending on their diagnostic status.  As a positive breast cancer 
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diagnosis is sometimes a traumatic experience, we expected that impairments in the 
positive diagnosis subgroup would remain stable or increase from pre- to post-biopsy 
while scores for the benign group would indicate improvement in terms of sleep and 
affect, along with a corresponding decrease in serum cytokines, after biopsy results were 
received.  These hypotheses were not confirmed.  Results indicated neither improvements 
in sleep quality or affect nor decreased levels of serum cytokines were noted in women 
who received a benign diagnosis.  Conversely, results for several scales indicated 
improved sleep quality for women diagnosed with breast cancer relative to women who 
received a benign diagnosis.  Results of repeated measures analysis that compared PSQI 
component scores for benign and positive diagnosis subgroups across time points 
indicated that women with a positive diagnosis demonstrated improved levels of sleep 
latency and daytime dysfunction relative to those with a benign diagnosis from pre- to 
post-biopsy.  In other words, women who were diagnosed with breast cancer showed 
improvements in the time it took to fall asleep and felt more rested after receiving their 
diagnosis relative to women who received a benign diagnosis.   
 Although these results were contrary to our hypotheses, they do provide further 
support for the argument that it is the experience of uncertainty that leads to the acute 
psychological distress consistently shown in women undergoing breast cancer screening 
and breast biopsy.  As was previously noted, uncertainty in illness occurs when an 
individual is made aware of the possibility that they might have a life-threatening disease 
without being able to immediately confirm positive or negative diagnosis (Jordens, Little, 
Paul, & Sayers, 2001).  Exposure to the period of uncertainty between detection of an 
abnormal breast mass and definitive breast cancer diagnosis has been shown to impact 
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both the beliefs and the behaviors of women who receive a benign diagnosis.  Studies 
have shown that women who have received a benign diagnosis following breast biopsy 
are less likely to comply with future recommended screening procedures (e.g. 
Andrykowski et al., 2002; Barton et al., 2004).  Increase breast cancer specific worry has 
also been shown in women who have received a benign breast biopsy as has heightened 
perceived 10-year and lifetime risks for eventual positive breast cancer diagnosis 
(Andrykowski et al., 2002).  Overall, evidence suggests that it is the experience of 
uncertainty that is causing the acute distress experienced by women undergoing breast 
biopsy.  If this is the case, then it is possible that receipt of a benign diagnosis serves to 
perpetuate feelings of uncertainty as women who receive such a diagnosis believe that 
they are at an increase risk for developing breast cancer in the future.  While receipt of a 
positive diagnosis is a frightening and traumatic experience, it also represents a resolution 
of uncertainty.  Under these circumstances, the results of the present study might indicate 
that women with a benign diagnosis fail to demonstrate improvements in sleep quality 
and affect because they continue to experience uncertainty around their long-term 
physical health.    
Results also indicated that both groups showed an increase in serum CRP from 
pre-to post biopsy time points regardless of the diagnosis that they received.  This finding 
provides further support for the impact of the acute stress experienced during breast 
cancer diagnostic testing on levels of this circulating pro-inflammatory cytokine.  No 
additional findings emerged in terms of levels of serum IL-6 or in terms of negative and 
positive affect scales.   
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Limitations and Future Directions.  Several limitations were apparent in the 
present study.  The primary limitation of this study was the size and diversity of the study 
sample, which primarily consisted of Caucasian women 50 years or older.  We were also 
limited in terms of demographic information regarding socioeconomic status, medical 
history, and family history of breast cancer diagnosis.  Due to the small number of 
participants overall and especially within the positive diagnosis group, it is possible that 
analyses were impacted by Type II error.  However, the measures included in the present 
study are novel and the results that were evidenced provide important direction for future 
research. 
 In order to continue to examine the role of uncertainty in the psychological 
distress demonstrated during breast cancer screening and diagnosis, future research 
should involve long-term research with larger and more diverse samples that would 
specifically examine this construct to determine how uncertainty impacts symptoms of 
psychological distress over time for women with benign breast biopsy.  If future research 
bears out the theory that uncertainty, along with associated psychological distress, 
persists beyond receipt of definitive diagnosis for women with benign breast biopsy, than 
this might be a fertile area for potential intervention.   
Summary.  Overall, results of the present study provide additional evidence for the 
negative psychological and physiological impact of breast cancer screening and 
diagnosis.  As sleep quality and positive and negative affect had not previously been 
examined within this population, the present study represents the first exploration of the 
impact of breast cancer screening on these important constructs.  Results indicated 
substantial elevations in terms of poor sleep quality and negative affect in this group 
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relative to normative samples as well as improved sleep latency and daytime dysfunction 
in the positive versus benign diagnosis group.  In keeping with prior research, results 
indicated increased levels of a biomarker of inflammation from pre-to post-biopsy time 
points.  Results also indicated a positive association between positive and negative affect 
for this sample, and positive and negative affect were shown to be predictive of each 
other from pre- to post-biopsy time points both for the group as a whole and for 
diagnostic subgroups.  These findings might provide initial support for the presence of 
broadly heightened emotionality occurring in women undergoing breast cancer diagnostic 
testing and might also provide an explanation for inconsistencies in prior research around 
the presence of depression symptoms in this population.  Finally, results of the present 
study provide some additional support for the importance of uncertainty in producing the 
acute psychological distress consistently reported in women undergoing breast cancer 
screening and breast biopsy.   
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Appendices 
TABLE I 
Demographic Information – Means and Frequencies 
 
 Total Positive 
Diagnosis 
Benign 
Diagnosis 
 
 
  
Age Mean Scores (SD) 52.93(10.67) 56.6(8.93) 51.22(11.11) 
Time 1 – Time 2 Interval 
mean scores (SD) 
 
25.5(26) 17.3(9.91) 29.58(30.61) 
Ethnicity 
Black, Non-Hispanic 
Hispanic 
White, Non-Hispanic 
Not Reported 
 
4.3% 
6.4% 
51.1% 
38.3% 
 
0% 
6.7% 
53.3% 
40% 
 
6.3% 
6.3% 
50% 
37.5% 
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TABLE IIa 
Descriptive Statistics, Mean Scores (SD) – Pre-biopsy 
 
 Total Positive Diagnosis Benign 
Diagnosis 
 
 
  
PSQI Index Score 7.28(3.5) 7.27(2.71) 7.28(3.86) 
PANAS Positive Affect  25.11(6.1) 25.2(5.11) 23.81(6.07) 
PANAS Negative Affect 29.79(6.34) 30.1(5.65) 29.66(6.72) 
CRP 
 
5612.32(4690.1) 4611.43(3918.59) 6079.4(5002.35) 
IL-6 133.7(248.87) 109.8(234.16) 144.82(258.55) 
    
 
 
TABLE IIb 
Descriptive Statistics, Mean Scores (SD) – Post-biopsy 
 
 Total Positive Diagnosis Benign 
Diagnosis 
 
 
  
PSQI Index Score 7.02(3.59) 6.86(3.84) 7.09(3.54) 
PANAS Positive Affect  23.74(6.51) 23.6(7.59) 29.81(6.07) 
PANAS Negative Affect 29.32(7.44) 27.53(9.0) 30.16 (6.58) 
CRP 
 
7048.24(5852.36) 7238.64(6561.77) 6962.2(5617.03) 
IL-6 130.69(238.04) 103.85(230.59) 143.22(244.28) 
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Table III 
Partial Correlations for PSQI, PANAS, CRP and IL-6 
 
 
Scale 
 
PSQI T1 
 
PSQI T2 
Panas  
Pos T1 
Panas  
Pos T2 
Panas 
Neg T1 
Panas  
Neg T2 
PSQI 
Total T1 
Total T2 
Benign T1 
Benign T2 
Positive T1 
Positive T2 
 
 
- 
.551* 
- 
.516* 
- 
.566* 
 
.551* 
- 
.516* 
- 
.566* 
- 
 
.078 
.032 
.075 
-.106 
-.204 
-.395 
 
-.105 
-.222 
.193 
.145 
-.105 
-.222 
 
 
-.008 
.186 
-.05 
.057 
-.008 
.186 
 
-.225 
-.168 
.028 
.087 
-.225 
-.168 
PANAS Pos 
Total T1 
Total T2 
Benign T1 
Benign T2 
Positive T1 
Positive T2 
 
 
.078 
-.105 
.075 
.193 
-.204 
-.376 
 
.032 
-.222 
-.106 
.145 
-.395 
-.422 
 
 
- 
.492* 
- 
.795* 
- 
.647 
 
.492 
- 
.795* 
- 
.492* 
- 
 
.798* 
.399* 
.851* 
.769* 
.798* 
.399* 
 
.466* 
.917* 
.753* 
.917* 
.466* 
.917* 
PANAS Neg 
Total T1 
Total T2 
Benign T1 
Benign T2 
Positive T1 
Positive T2 
 
 
-.008 
-.225 
-.05 
.028 
.132 
-.352 
 
.186 
-.168 
.057 
.087 
.103 
-.107 
 
.798* 
.466* 
.851* 
.753* 
.824* 
.712† 
 
.399* 
.917* 
.769* 
.917* 
.798* 
.466* 
 
- 
.459* 
- 
.680* 
- 
.459* 
 
.459* 
- 
.680* 
- 
.459* 
- 
CRP 
Total T1 
Total T2 
 Benign T1 
Benign T2 
Positive T1 
Positive T2 
 
 
.338† 
.271 
.372 
.429† 
.419 
.008 
 
.384* 
.375* 
.407 
.482* 
.687† 
.567 
 
.049 
-.138 
-.083 
-.191 
.049 
-.138 
 
-.060 
-.160 
.123 
.137 
.049 
-.138 
 
.225 
.043 
-.058 
-.104 
.225 
.043 
 
-.079 
-.146 
-.028 
.044 
-.079 
-.146 
IL-6 
Total T1  
Total T2 
 Benign T1 
Benign T2 
Positive T1 
Positive T2 
 
 
.256 
.258 
.405 
.393 
.419 
.987 
 
 
.128 
.063 
.270 
.254 
.397 
.624  
 
.128 
.063 
.219 
.193 
.128 
.063 
 
.233 
.195 
.219 
.193 
.128 
.063 
 
 
.027 
-.021 
.024 
.013 
.027 
-.021 
 
.253 
.214 
.197 
.195 
.253 
.214 
* p >.05   † p< .10 
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Figure A.  Pre- to Post-biopsy changes in CRP by diagnostic subgroup. 
       
 
Figure B.  Pre- to post-biopsy changes in Pittsburgh Sleep Quality Index Sleep Latency component scores 
by diagnostic subgroup. 
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Figure B.  Pre- to post-biopsy changes in Pittsburgh Sleep Quality Index Daytime Dysfunction component 
scores by diagnostic subgroup. 
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Appendix: European Organization for Research and Treatment of Cancer Quality of Life 
Questionnaire  (EORTC)  *  
* The EORTC QLQ-C30 is a copyrighted instrument. It is currently available in the 
following languages: Danish, Dutch, French, German, Italian, Japanese, Norwegian, and 
Swedish. Requests for permission to use the instrument and for scoring instructions 
should be sent either to Neil K. Aaronson, Ph.D., The Netherlands Cancer Institute, 
Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands, or to Ann Cull, Ph.D., 
Secretary, EORTC Study Group on Quality of Life, Department of Clinical Psychology, 
Outpatient Clinic E, Western General Hospital, Crewe Road, Edinburgh EH4 2XU, 
United Kingdom. 
We are interested in some things about you and your health. Please answer all of the 
questions yourself by circling the number that best applies to you. There are no "right" or 
"wrong" answers. The information that you provide will remain strictly confidential. 
Please fill in your initials: 
Your birthdate (Day, Month, Year): 
Today's date (Day, Month, Year):  
 No Yes 
1. Do you have any trouble doing strenuous 
ac- 
  
tivities, like carrying a heavy shopping bag or 
  
a suitcase? 1 2 
 
  
2. Do you have any trouble taking a long 
walk? 1 2 
 
  
3. Do you have any trouble taking a short walk 
  
outside of the house? 1 2 
 
  
4. Do you have to stay in a bed or a chair for 
  
most of the day? 1 2 
 
  
5. Do you need help with eating, dressing, 
wash- 
  
ing yourself or using the toilet? 1 2 
 
  
6. Are you limited in any way in doing either 
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your work or doing household jobs? 1 2 
 
  
7. Are you completely unable to work at a job 
or 
  
to do household jobs? 1 2 
DURING THE PAST WEEK: 
 
Not 
at A Quite Very 
 All Little a Bit Much 
8. Were you 
short of 
    
breath? 1 2 3 4 
 
    
9. Have you 
had pain? 1 2 3 4 
 
    
10. Did you 
need to rest? 1 2 3 4 
 
    
11. Have you 
had trouble 
    
sleeping? 1 2 3 4 
 
    
12. Have you 
felt weak? 1 2 3 4 
 
    
13. Have you 
lacked 
    
appetite? 1 2 3 4 
 
    
14. Have you 
felt 
    
nauseated? 1 2 3 4 
 
    
15. Have you 
vomited? 1 2 3 4 
 
    
16. Have you 
been 
    
constipated? 1 2 3 4 
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17. Have you 
had 
    
diarrhea? 1 2 3 4 
 
    
18. Were you 
tired? 1 2 3 4 
 
    
19. Did pain 
interfere with 
    
your daily 
activities? 1 2 3 4 
 
    
20. Have you 
had diffi- 
    
culty in 
concentrating 
    
on things, 
like reading 
    
a newspaper 
or watch- 
    
ing 
television? 1 2 3 4 
 
    
21. Did you 
feel tense? 1 2 3 4 
 
    
22. Did you 
worry? 1 2 3 4 
 
    
23. Did you 
feel irritable? 1 2 3 4 
 
    
24. Did you 
feel 
    
depressed? 1 2 3 4 
 
    
25. Have you 
had 
    
difficulty 
remembering 
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things? 1 2 3 4 
 
    
26. Has your 
physical 
    
condition or 
medical 
    
treatment 
interfered 
    
with your 
family life? 1 2 3 4 
 
    
27. Has your 
physical con- 
    
dition or 
medical 
    
treatment 
interfered 
    
with your 
social 
    
activities? 1 2 3 4 
 
    
28. Has your 
physical con- 
    
dition or 
medical 
    
treatment 
caused you 
    
financial 
difficulties? 1 2 3 4 
FOR THE FOLLOWING QUESTIONS PLEASE CIRCLE THE NUMBER BETWEEN 
1 AND 7 THAT BEST APPLIES TO YOU 
29. How would you rate your overall physical condition during the past week?  
1 2 3 4 5 6 7 
Very 
poor      Excellent 
30. How would you rate your overall quality of life during the past week?  
1 2 3 4 5 6 7 
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Very 
poor      Excellent 
 
Appendix: Hospital Anxiety and Depression Scale (HADS) 
Hospital Anxiety and Depression Scale (HADS) 
Patients are asked to choose one response from the four given for each 
interview.   They should give an immediate response and be dissuaded 
from thinking too long about their answers.  The questions relating to 
anxiety are marked "A", and to depression "D".  The score for each answer 
is given in the right column.  Instruct the patient to answer how it currently 
describes their feelings. 
  
A I feel tense or 
'wound up': 
  
  Most of the time 3 
  A lot of the time 2 
  From time to time, 
occasionally 1 
  Not at all 0 
  
D 
I still enjoy the 
things I used to 
enjoy: 
  
  Definitely as much 0 
  Not quite so much 1 
  Only a little 2 
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  Hardly at all 3 
  
A 
I get a sort of 
frightened feeling 
as if something 
awful is about to 
happen: 
  
  Very definitely and 
quite badly 3 
  Yes, but not too 
badly 2 
  A little, but it 
doesn't worry me 1 
  Not at all 0 
  
D 
I can laugh and see 
the funny side of 
things: 
  
  As much as I always 
could 0 
  Not quite so much 
now 1 
  Definitely not so 
much now 2 
  Not at all 3 
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A 
Worrying thoughts 
go through my 
mind: 
  
  A great deal of the 
time 3 
  A lot of the time 2 
  From time to time, 
but not too often 1 
  Only occasionally 0 
  
D I feel cheerful:   
  Not at all 3 
  Not often 2 
  Sometimes 1 
  Most of the time 0 
  
A I can sit at ease 
and feel relaxed:   
  Definitely 0 
  Usually 1 
  Not Often 2 
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  Not at all 3 
  
D I feel as if I am 
slowed down:   
  Nearly all the time 3 
  Very often 2 
  Sometimes 1 
  Not at all 0 
  
A 
I get a sort of 
frightened feeling 
like 'butterflies' in 
the stomach: 
  
  Not at all 0 
  Occasionally 1 
  Quite Often 2 
  Very Often 3 
  
D I have lost interest 
in my appearance:   
  Definitely 3 
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  I don't take as much 
care as I should 2 
  I may not take quite 
as much care 1 
  I take just as much 
care as ever 0 
  
A 
I feel restless as I 
have to be on the 
move: 
  
  Very much indeed 3 
  Quite a lot 2 
  Not very much 1 
  Not at all 0 
  
D 
I look forward with 
enjoyment to 
things: 
  
  As much as I ever 
did 0 
  Rather less than I 
used to 1 
  Definitely less than I 
used to 2 
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  Hardly at all 3 
  
A I get sudden 
feelings of panic:   
  Very often indeed 3 
  Quite often 2 
  Not very often 1 
  Not at all 0 
  
D 
I can enjoy a good 
book or radio or TV 
program: 
  
  Often 0 
  Sometimes 1 
  Not often 2 
  Very seldom 3 
  
  
Scoring (add the As = 
Anxiety.  Add the Ds 
= Depression).  The 
norms below will give 
you an idea of the 
level of Anxiety and 
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Depression. 
  0-7 = Normal   
  8-10 = Borderline 
abnormal   
  11-21 = Abnormal   
      
 
Reference: 
Zigmond and Snaith (1983) 
  
Appendix: Positive and Negative Affect Schedules (PANAS) 
PANAS 
 
This scale consists of a number of words that describe different feelings and emotions.  Read 
each item and then circle the appropriate answer next to that word.  Indicate to what extent 
you have felt this way during the past week. 
 
 
1 = Very slightly or not at all     2 = A little     3 = Moderately      4 = Quite a bit    5 = Extremely 
 
1. Interested 1 2 3 4 5 
2. Distressed 1 2 3 4 5 
3. Excited 1 2 3 4 5 
4. Upset 1 2 3 4 5 
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5. Strong 1 2 3 4 5 
6. Guilty 1 2 3 4 5 
7. Scared 1 2 3 4 5 
8. Hostile 1 2 3 4 5 
9. Enthusiastic 1 2 3 4 5 
10. Proud 1 2 3 4 5 
11. Irritable 1 2 3 4 5 
12. Alert 1 2 3 4 5 
13. Ashamed 1 2 3 4 5 
14. Inspired 1 2 3 4 5 
15. Nervous 1 2 3 4 5 
16. Determined 1 2 3 4 5 
17. Attentive 1 2 3 4 5 
18. Jittery 1 2 3 4 5 
19. Active 1 2 3 4 5 
20. Afraid 1 2 3 4 5 
  
